<DOC>
	<DOCNO>NCT01327183</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled study evaluate efficacy safety RO4905417 patient non ST-elevation myocardial infarction ( Non-STEMI ) undergo percutaneous coronary intervention ( PCI ) . Patients randomize receive intravenous infusion either 5 mg/kg RO4905417 20 mg/kg RO4905417 placebo PCI . Follow-up 4 month .</brief_summary>
	<brief_title>A Study RO4905417 Patients With Non ST-Elevation Myocardial Infarction ( Non-STEMI ) Undergoing Percutaneous Coronary Intervention</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<criteria>Adult patient , &gt; 18 &lt; 75 year age Non STelevation myocardial infarction Woman childbearing potential allow use two acceptable method contraception Body mass index ( BMI ) &lt; /= 40 kg/m2 Acute STelevation myocardial infarction ( STEMI ) Culprit coronary lesion total thrombotic occlusion lesion require use distal embolization protection thrombectomy device Percutaneous coronary intervention ( PCI ) within past 72 hour Thrombolytic therapy within past 7 day Major surgery within past 3 month History cerebral vascular disease stroke past 3 month Bleeding disorder Inadequately control severe hypertension Prior coronary artery bypass graft ( CABG ) surgery Decompensated heart failure ( oedema and/or rale ) Acute infection screen active chronic infection within 3 month prior PCI Patients known HIV positive , patient receive antiretroviral drug , immunosuppressed patient Uncontrolled diabetes mellitus ( HbA1C &gt; 10 % ) baseline</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>